Plus Therapeutics (PSTV) Business update summary

Financial Update and Capital Position

• Completed an oversubscribed $15 million offering, extending cash runway through 2027 and enabling growth initiatives.

• Ongoing access to three grants (CPRIT, NIH, DOD) fully funds clinical milestones through 2027.

• No immediate plans for a reverse stock split; focus remains on execution and generating positive catalysts.

• Progress depends on successful capital raising, clinical trial completion, and economic conditions.

Market Opportunity and Unmet Needs

• Over 1 million U.S. patients are at risk of CNS metastases, with up to 30% of adult cancer patients developing CNS mets.

• CNSide diagnostic platform targets a $6B U.S. market, with a projected 500,000 patients per year and a commercial relaunch planned for Q3 2025.

• REYOBIQ radiotherapeutic addresses a $16B U.S. market, offering up to 20x radiation delivery versus standard of care.

Diagnostic and Therapeutic Innovation

• CNSide offers a comprehensive, highly sensitive tumor cell capture and interrogation system, with 95% specificity and 92% sensitivity, and over 11,000 tests completed.

• The platform provides four tests from a single sample, enabling diagnosis, treatment monitoring, and personalized therapy selection.

• REYOBIQ is a first-in-class targeted injectable radiotherapy for CNS tumors, leveraging rhenium-186 for both treatment and imaging.